John V. Oyler (born April 3, 1968) is an American businessman, who is a co-founder, chairman, and CEO of BeiGene, a global oncology pharmaceutical company. He is also a board member of the Biotechnology Innovation Organization (BIO).[1][2]
John V. Oyler | |
|---|---|
| Born | April 3, 1968 |
| Citizenship | American |
| Education | |
| Occupation | Businessman |
Early life and education
editOyler was born on April 3, 1968, in Pittsburgh, Pennsylvania. He attended Mt. Lebanon High School, where he first developed his interest in science. While in high school, his scientific research and presentations won awards from Westinghouse in 1985 and 1986, respectively.[3][4]
He holds a bachelor of science in mechanical engineering from Massachusetts Institute of Technology (MIT) and a master of business administration from Stanford Graduate School of Business.[5][1]
Career
editOyler started his business career while studying at MIT, selling and renting student supplies in the Boston area.[5] After his undergraduate degree, he joined McKinsey & Company, where he served as a consultant while attending Stanford Graduate School of Business.[1]
In 1997, he founded Telephia, which was later sold to Nielsen Co. in 2007. Oyler later launched a contract research organization, BioDuro, in 2005, and it was sold to PPD in 2010.[1][6][7]
Along with Xiaodong Wang, he co-founded BeiGene in 2010 to develop affordable and accessible life-saving oncology medications. Oyler invested $10 million to start BeiGene and secured funding from other angel investors and Merck & Co., becoming its CEO and chairman.[8][9] In 2019, he joined Biotechnical Innovation Organization (BIO) as its board member.[2]
As of 2024, Oyler is serving as the CEO and chairman of BeiGene and a board member of the Biotechnical Innovation Organization (BIO).[1][2][10]
References
edit- ^ a b c d e "How — And Why — John Oyler Built BeiGene". www.lifescienceleader.com. Retrieved September 17, 2024.
- ^ a b c "CEO of China health care start-up works hard on cancer drugs pipeline". South China Morning Post. October 16, 2017. Retrieved September 17, 2024.
- ^ "Science winners go to international fair". The Pittsburgh Press. April 6, 1986. p. 33. Retrieved September 17, 2024 – via Newspapers.com.
- ^ "Science". The Pittsburgh Press. April 3, 1985. p. 21. Retrieved September 17, 2024.
- ^ a b "A Vision of Affordability". PharmExec. March 29, 2023. Retrieved September 17, 2024.
- ^ "Drug R&D Heats Up In Beijing". Chemical & Engineering News. Retrieved September 17, 2024.
- ^ Wallace, Claire (October 14, 2022). "A new name joins Forbes' growing list of healthcare billionaires". www.beckersasc.com. Retrieved September 17, 2024.
- ^ "BeiGene Brings Biotech to China". Bloomberg.com. July 7, 2011. Retrieved September 17, 2024.
- ^ Bergeron, Tom (July 23, 2024). "BeiGene's global goal: Create great medicines — and make them accessible (and affordable) to all". ROI-NJ. Retrieved September 17, 2024.
- ^ Bergeron, Tom (July 23, 2024). "BeiGene ribbon-cutting: Big get for life science industry — and bigger vote of confidence for state". ROI-NJ. Retrieved September 17, 2024.
 | This business-related biographical article is a stub. You can help Wikipedia by expanding it. |
This article needs additional or more specific categories. (September 2024) |